• Home
  • NASH Emerging Topic Conference

Register Today for the 2023 Emerging Topic Conference: NASH Cirrhosis: From Mechanisms to Management

Together, we can tackle NASH Cirrhosis. Don’t miss the 2023 Emerging Topic Conference: NASH Cirrhosis: From Mechanisms to Management, a joint event between the Fibrosis SIG and NAFLD SIG to discuss the most recent research in NASH cirrhosis in a bench-to-bedside approach. 

Attendees can network with others interested in NASH cirrhosis and will get expert updates on:

-New mechanisms in reversing fibrosis in patients with NASH.

-New therapeutic agents to treat NASH cirrhosis.

-New clinical trials and regulatory science in the field of NASH cirrhosis.

You can register for this event alone or for the combo of the North American Viral Hepatitis Elimination Summit and NASH Cirrhosis Emerging Topic Conference.

Register Now

When & Where

Date: Saturday, March 25, 10:00 am - Sunday, March 26, 4:30 pm (EDT)
Location: JW Marriott Los Angeles L.A. Live | 900 West Olympic Boulevard | Los Angeles, CA 90015

Program Chairs

Learning Objectives

  • Learn about new mechanisms in reversing fibrosis in patients with NASH
  • Learn about new therapeutic agents to treat NASH cirrhosis
  • Learn about new clinical trials and regulatory science in the field of NASH cirrhosis

Target Audience:

  • Hepatologists
  • Gastroenterologists
  • Nurse Practitioners
  • Pharmacists
  • Surgeons
  • Fellows/Trainees

Continuing Education

Continuing Medical Education (CME): 9.50 AMA PRA Category 1 Credits™

ABIM MOC points: 9.50 MOC points

Travel Note

US residents: Please review the Real ID Act regarding boarding federally regulated commercial aircrafts. Due to circumstances resulting from the COVID-19 pandemic, the Department of Homeland Security has extended the REAL ID enforcement deadline to May 7, 2025. Depending on your state of residence, you may need to provide a second form of identification at the airport.

Schedule Note

Please note, all times in the agenda are listed in Pacific Daylight Time (PDT) as this is an in-person only event in Los Angeles, CA.

Tentative Agenda - March 25, 2023

Session I: Epidemiology, Genetics and Epigenetics

Moderators: Robert F. Schwabe, MD and Mazen Noureddin, MD

8:00 - 8:05 am               Welcome and Opening Remarks
8:05 - 8:30 am               Epidemiology and Disease Burden of NASH Cirrhosis
                                       Zobair M. Younossi, MD, MPH, FAASLD
8:30 - 8:55 am               Ethnic and Gender Differences of NASH Cirrhosis
                                       Lisa Van Wagner, MD
8:55 - 9:20 am               State of Art-Lecture: Role of Genetics and Epigenetics in NASH Cirrhosis
                                       Anna Mae Diehl, MD, FAASLD
9:20 - 9:40 am               Q&A
9:40 - 10:20 am            Break

Session II: Biomarkers: Bench to Bedside

Moderators: Ekihiro Seki, MD, PhD, FAASLD and Alina Allen, MD

10:20 - 10:45 am        NAFLD Fibrosis Mechanism and Biomarkers: What’s on the Horizon in Pre-clinical Models?
                                     Ekihiro Seki, MD, PhD, FAASLD
10:45 - 11:10 am        Non-coding RNA and EVs in NASH Cirrhosis
                                     Harmeet Malhi, MBBS, FAASLD
11:10 - 11:35 am        The Microbiome: Therapeutic Target, Marker or Both?
                                     Rohit Loomba, MD
11:35 - 11:55 am        Q&A
11:55 am - 1:00 pm   Break

Session III: Study Design: Pre-Clinical and Clinical

Moderators: Stephen A. Harrison, MD, FAASLD and Mary Rinella, MD, FAASLD

1:00 – 1:25 pm       Therapeutic Targets in NASH: Discovery in Mice or Men?
                                     Scott L. Friedman, MD, FAASLD
1:25 – 1:50 pm       Human Studies Proof of Concept Design and Related Biomarkers
                                     Laurent Castera, MD
1:50 – 2:15 pm       Designing Clinical Trial in NASH Cirrhosis
                                     Stephen A. Harrison, MD, FAASLD
2:15 – 2:40 pm       Clinical Trial in NASH Cirrhosis: The Regulator Perspective
                                     George Makar, MD, MSCR
2:40 – 3:05 pm       Debate: The Decompensated NASH Cirrhotic: Too Late to Treat?
                                     Meena Bansal, MD, FAASLD
3:05 – 3:30 pm       Debate: Hepatic Safety in NASH Cirrhosis Clinical Trials
                                     Naga P. Chalasani MD, FAASLD
3:30 – 3:50 pm       Q & A
5:00 - 6:30 pm       Networking Reception

Tentative Agenda - March 26, 2023

Session IV: Mechanisms and Cellular Targets

Moderators: Anna Mae Diehl, MD, FAASLD and David A. Brenner, MD 

8:00 - 8:05 am       Opening Remarks
8:05 - 8:30 am       Single Cell-based Analysis of Cellular Crosstalk in Human NASH and Fibrosis
                               Sonya MacParland, PhD
8:30 - 8:55 am       Targeting Hepatic Stellate in NASH
                               Robert F. Schwabe, MD
8:55 - 9:20 am       Targeting Hepatocyte Metabolism
                               Dongyin Guan, PhD
9:20 - 9:45 am       Understanding and Targeting Macrophages in NASH
                              Neil Henderson, MD, MBChB, PhD
9:45 - 10:05 am     Q & A
10:05 - 10:25         Break

Session V: Therapeutic Targets

Moderators: Meena Bansal MD, FAASLD and Naga P. Chalasani, MD, FAASLD

10:25 - 10:45 am       Targeted Pathways in NASH Cirrhosis
                                     Silvia Sookoian, MD, PhD
10:45 - 11:00 am       Debate: GLP-1 in NASH Cirrhosis 
                                     Jörn M. Schattenberg, MD
11:00 - 11:15 am        Debate: FGFs in NASH Cirrhosis
                                     Mazen Noureddin, MD
11:15 - 11:30 am        Debate: Drugs Targeting DNL in NASH Cirrhosis
                                     Kathleen Corey, MD
11:30 - 11:45 am        Debate: PPAR in NASH Cirrhosis
                                     Manal F. Abdelmalek, MD, MPH, FAASLD
11:45 - 12:45 pm       Lunch
12:45 - 1:00 pm          Debate: Thyroid Hormone Receptors in NASH Cirrhosis
                                     Naim Alkhouri, MD
1:00 - 1:15 pm            Debate: FXRs in NASH Cirrhosis 
                                   Arun J. Sanyal, MD, FAASLD
1:15 - 1:30 pm           Other Agents and Combination Therapies
                                    Mary Rinella, MD, FAASLD
1:30 - 1:50 pm            Q & A

Session VI: NASH and Cirrhosis Consortia

Moderator: Neil C. Henderson, MD, MBChB, PhD, FAASLD and Ekihiro Seki, M, PhD, FAASLD

1:50 - 2:05 pm             An Update from the NASH CRN
                                     Brent Tetri, MD, FAASLD
2:05 - 2:20 pm             The NIDDK Liver Cirrhosis Network and Statin Trial
                                     Norah Terrault, MD, FAASLD
2:20 - 2:40 pm             Q & A
2:40 pm                       Conference Adjourned
                                     Anna Mae Diehl, MD, FAASLD

Registration Rates: NASH Cirrhosis: From Mechanisms to Management

General

Any physician, scientist, or researcher with doctoral-level training who is not employed by Industry (pharma/device/etc.)

Member Non-Member
On or After February 24, 2023 $450 $670

Trainee & Associate

Any physician, scientist or researcher in a training program as certified by the director of their training program. This category also includes, but is not limited to, the degrees of MS, NP, PA, RN, and other related or comparable degrees.

Member Non-Member
On or After February 24, 2023 $220 $275

Student

Member Non-Member
On or After February 24, 2023 $110 $135

Industry

Any Industry (pharma/device/etc.) employee with or without medical training.

Industry
On or After February 24, 2023 $920

Patients, Patient Advocates and Caregivers

Patients, Patient Advocates and Caregivers
Rate Complimentary

Registration Combo-Pricing for the North American Viral Hepatitis & NASH Cirrhosis Emerging Topic Conference

General

Any physician, scientist, or researcher with doctoral-level training who is not employed by Industry (pharma/device/etc.)

Member Non-Member
On or After February 24, 2023 $630 $940

Trainee & Associate

Any physician, scientist or researcher in a training program as certified by the director of their training program. This category also includes, but is not limited to, the degrees of MS, NP, PA, RN, and other related or comparable degrees.

Member Non-Member
On or After February 24, 2023 $310 $390

Student

Member Non-Member
On or After February 24, 2023 $150 $190

Industry

Any Industry (pharma/device/etc.) employee with or without medical training.

Industry
On or After February 24, 2023 $1,290

Patients, Patient Advocates and Caregivers

Patients, Patient Advocates and Caregivers
Rate Complimentary

Registration Cancellation Policy

Requests for cancellations must be submitted in writing to meetings@aasld.org.

Cancellations received by Thursday, February 23, 2023 will be refunded in full.

Cancellations received between February 24 – March 6, 2023 will be subject to a $50.00 cancellation fee.

Cancellations received on or after March 7, 2023 are not eligible for a refund.

Housing

JW Marriott Los Angeles L.A. Live 
900 W Olympic Blvd
Los Angeles, CA, 90015
Phone: 213-765-8600

Reserve your hotel today!

*When calling to make a reservation, please let the hotel representative know that you are attending the AASLD NASH Cirrhosis Conference.

Single/Double $259 per night plus tax

Discounted rates are available until March 3, 2023.

Cancel your reservation for no charge until 72 hours prior to your arrival date.

Please note that the hotel will assess a fee of (1) night of your room charge (for the first night of your reservation) USD if you must cancel after this deadline.

Valet Daily: $53.90

Electric Car Charging Station Available

Los Angeles International Airport (LAX) - 17.2 miles from hotel

Hollywood Burbank Airport (BUR) - 16 miles from hotel